GLPwatch
dulaglutide (Trulicity°) weekly in type 2 diabetes: Cardiovascular reactions should be better documented.
Prescrire Int · 2016
Last updated 2026-05-28In four studies with over 3,000 participants, dulaglutide (Trulicity) lowered blood sugar levels as effectively as other similar drugs when combined with existing diabetes treatments. However, its long-lasting effects may complicate handling side effects or drug interactions, and more research is needed to understand its impact on heart health.
AI summary of the abstract below.
| Journal | Prescrire Int, 2016 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | dulaglutide |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction |
Abstract
In four trials including a total of more than 3000 patients, dulaglutide reduced the HbA1c concentration as effectively as other GLP-1 analogues when added to other hypoglycaemic drugs. The long elimination half-life of dulaglutide can make management of adverse effects and drug interactions more difficult. More data are needed on possible cardiac adverse effects.
Verbatim abstract via PubMed 30645827 ↗
Related research
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
- Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
- Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
- Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).